Method for treating squamous non-small cell lung cancer by anti-PD-1 antibody or antigen-binding fragment thereof

Abstract

The invention relates to application of an anti-PD-1 antibody or an antigen binding fragment thereof in a medicine for treating squamous non-small cell lung cancer. The invention also provides a single drug dosage unit and a kit comprising an effective amount of an anti-PD-1 antibody or antigen-binding fragment thereof. The invention further provides application of the single drug dosage unit or the kit in preparation of drugs for treating squamous non-small cell lung cancer, and preferably, the squamous non-small cell lung cancer is advanced or metastatic squamous non-small cell lung cancer caused by failure of first-line platinum-containing chemotherapy.

Description

technical field [0001] The present invention relates to a method for treating squamous non-small cell lung cancer with an anti-PD-1 antibody or an antigen-binding fragment thereof, and to a use of the anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a medicine for treating squamous non-small cell lung cancer. Background technique [0002] With the prolongation of human life expectancy and the change of life style, malignant tumor has become a serious threat to the health of Chinese people and constitutes a major disease that threatens life. Lung cancer, in particular, ranks first among malignant tumors in its morbidity and mortality due to the huge smoking population. According to statistics in 2015, the incidence and death rate of lung cancer in China were 733,000 and 600,000, respectively, the highest in the world [http: / / globocan.iarc.fr / Default.aspx]. There are few effective treatments for advanced squamous cell carcinoma of the lung. The first-lin...

AI Technical Summary

Problems solved by technology

The effect of second-line therapy is limited, and the median survival time is about 6 months [Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015,373:123-135], there is a great unmet medical need

[0005] In view of the limited effect of docetaxel in the treatment of second-line squamous non-small cell lung cancer, such as the short median overall survival time, it is urgent to explore immune checkpoint inhibition Agents in second-line squamous non-small cell lung cancer treatment strategy

Images